Back to results
US 10,869,861 B2Granted
Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome
AssigneeThe Children's Hospital of Philadelphia
InventorsHakon Hakonarson, Charlly Kao
Life of this patent
Estimating the term…
Abstract
This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.
Claims10
A method of treating 22q deletion syndrome comprising:
- administering an effective amount of fasoracetam to a subject with 22q deletion syndrome and ADHD, thereby treating the 22q deletion syndrome, wherein symptoms of impulsiveness, hyperactivity, and/or inattentiveness are reduced in the subject following administration of fasoracetam wherein the fasoracetam is administered at a dose of 50-400 mg once, twice, or three times daily.
A method of treating 22q deletion syndrome comprising:
- administering an effective amount of fasoracetam to a subject with 22q deletion syndrome and ADHD, thereby treating the 22q deletion syndrome, wherein symptoms of impulsiveness, hyperactivity, and/or inattentiveness are reduced in the subject following administration of fasoracetam, wherein the fasoracetam is administered in an amount effective to result in a clinical general impression improvement (CGI-I) score of 1 or 2 after four weeks of treatment and/or an improvement of at least 25% in an ADHD rating scale score after four weeks of treatment.
A method of treating 22q deletion syndrome comprising:
- administering an effective amount of fasoracetam to a subject with 22q deletion syndrome and ADHD, thereby treating the 22q deletion syndrome, wherein symptoms of impulsiveness, hyperactivity, and/or inattentiveness are reduced in the subject following administration of fasoracetam, wherein the fasoracetam is administered in an amount effective to result in an improvement of at least 40% in an ADHD rating scale score after four weeks of treatment.
Dependencies are inferred from the claim text.